Proinflammatory cytokines VEGFA, IL-6, IL-8 as markers of hepatotoxicity after COVID-19
https://doi.org/10.15789/1563-0625-PCV-2843
Abstract
The mechanism of hepatocellular liver damage after COVID-19 is a multifactorial process. The most widely discussed causes are cytolytic liver damage due to the inflammatory response after COVID-19, drug-induced hepatotoxicity and direct cytotoxic effect of the virus. There are observations that SARSCoV-2 infection causes hepatitis B virus reactivation, but little has been described about the interaction between hepatitis C virus and SARS-CoV-2. The course of coronavirus infection is associated with marked expression of proinflammatory cytokines, participants in the multisystem inflammatory response, IL-1β, IL-6, IL-8, IL-18, MCP-1, TNFα, which contribute significantly to the observed early and late liver function impairment. The aim of the study was to evaluate the role of proinflammatory cytokines (VEGFA, IL-8, IL-6, MCP-1, TNFα, IL-18) as additional markers of hepatotoxicity after COVID-19. The study was performed between March and August 2022. Patients were divided into 2 groups: Group 1 – with increased aminotransferases against the background of treatment from COVID-19 and/or in the following 3-6 months after the disease without viral liver damage (n = 42), Group 2 – patients with co-infection (chronic viral hepatitis C (HCV) and COVID-19 (n = 26). The levels of cytokines – VEGF-A, IL-6, IL-8, MCP-1, IL-18, TNFα in blood serum were estimated by enzyme immunoassay method. Statistical analysis was performed using StatTech v. 3.1.4. The results of the study revealed a comparable increase in the level of transaminases and C-reactive protein in both groups, significantly different from the reference values. Direct correlations of moderate strength (linear Spearman correlation) were found between the following cytokines: TNFα-MCP-1 (R = 0.559; p = 0.001), TNFα-VEGFA (R = 0.400; p = 0.002), TNFα-IL-6 (R = 0.503; p = 0.001). We diagnosed a significant increase in serum VEGFA levels in group 1 patients (hepatotoxicity after COVID-19) (Me (Q0.25-Q0.75): 522 (250 to 1002), p = 0.001) and in group 2 patients (HCV + COVID-19) (Me 1196, Q0.25-Q0.75: (73 to 432). Similar trend with the level of IL-6, IL-8, exceeding the values of cytokines in healthy donors and significantly higher than in group 2 patients. Identified correlations between inflammatory cytokines prove unidirectional changes in the functioning of the regulatory network controlling immune virus-induced reactions.
About the Authors
M. A. UrevskiiRussian Federation
Urevskii M.A., Student, Faculty of Medicine, Institute of Medicine, Ecology, and Physical Education, Research Intern at the S. Kapitza Technological Research Institute
Ulyanovsk
L. V. Ilmukhina
Russian Federation
Ilmukhina L.V., PhD (Medicine), Associate Professor, Department of Dermatovenerology and Infectious Diseases, Faculty of Medicine, Institute of Medicine, Ecology, and Physical Education
Ulyanovsk
Ya. E. Saranskaya
Russian Federation
Saranskaya Ya.E., Senior Lecturer, Department of Dermatovenerology and Infectious Diseases, Faculty of Medicine, Institute of Medicine, Ecology, and Physical Education
Ulyanovsk
A. A. Lapshin
Russian Federation
Lapshin A.A., Student, Faculty of Medicine, Institute of Medicine, Ecology, and a medical student at the Institute of Medicine, Ecology, and Physical Education
Ulyanovsk
R. R. Gafurova
Russian Federation
Gafurova R.R., Student, Faculty of Medicine, Institute of Medicine, Ecology, and a medical student at the Institute of Medicine, Ecology, and Physical Education
Ulyanovsk
References
1. Alqahtani S.A., Schattenberg J.M. Liver injury in COVID-19: The current evidence. United European Gastroenterol J., 2020, Vol. 8, no. 5, pp. 509-519.
2. Bzeizi K., Abdulla M., Mohammed N., Alqamish J., Jamshidi N., Broering D. Effect of COVID-19 on liver abnormalities: a systematic review and meta-analysis. Sci. Rep., 2021, Vol. 11, no. 1, 10599. doi: 10.1038/s41598-021-89513-9.
3. Cabibbo G., Rizzo G.E.M., Stornello C., Craxì A. SARS-CoV-2 infection in patients with a normal or abnormal liver. J. Viral Hepat., 2021, Vol. 28, no. 1, pp. 4-11.
4. Cao Y. The impact of the hypoxia-VEGF-vascular permeability on COVID-19-infected patients. Exploration (Beijing), 2021, Vol. 1, no. 2, 20210051. doi: 10.1002/EXP.20210051.
5. Devaux C.A., Lagier J.C. Unraveling the underlying molecular mechanism of ‘Silent Hypoxia’ in COVID-19 patients suggests a central role for angiotensin II modulation of the AT1R-hypoxia-inducible factor signaling pathway. J. Clin. Med., 2023, Vol. 12, no. 6, 2445. doi: 10.3390/jcm12062445.
6. Dufour J.F., Marjot T., Becchetti C., Tilg H. COVID-19 and liver disease. Gut, 2022, Vol. 71, no. 11, pp. 2350-2362.
7. Kruse R.L. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. F1000Res., 2020, Vol. 9, 72. doi: 10.12688/f1000research.22211.2.
8. Lu X.H., Yang J.L., Deng K. COVID-19 Patients With Hepatitis B Virus Infection. Am. J. Gastroenterol., 2021, Vol. 116, no. 6, pp. 1357-1358.
9. Ozkurt Z, Çınar Tanrıverdi E. COVID-19: Gastrointestinal manifestations, liver injury and recommendations. World J. Clin. Cases, 2022, Vol. 10, no. 4, pp. 1140-1163.
10. Sodeifian F., Seyedalhosseini Z.S., Kian N., Eftekhari M., Najari S., Mirsaeidi M., Farsi Y., Nasiri M.J. DrugInduced Liver Injury in COVID-19 Patients: A Systematic Review. Front. Med. (Lausanne), 2021, Vol. 8, 731436. doi: 10.3389/fmed.2021.731436.
11. Wong G.L., Wong V.W., Thompson A., Jia J., Hou J., Lesmana C.R.A., Susilo A., Tanaka Y., Chan W.K., Gane E., Ong-Go A.K., Lim S.G., Ahn S.H., Yu M.L., Piratvisuth T., Chan H.L.; Asia-Pacific Working Group for Liver Derangement during the COVID-19 Pandemic. Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. Lancet Gastroenterol. Hepatol., 2020, Vol. 5, no. 8, pp. 776-787.
Supplementary files
Review
For citations:
Urevskii M.A., Ilmukhina L.V., Saranskaya Ya.E., Lapshin A.A., Gafurova R.R. Proinflammatory cytokines VEGFA, IL-6, IL-8 as markers of hepatotoxicity after COVID-19. Medical Immunology (Russia). 2023;25(4):803-808. https://doi.org/10.15789/1563-0625-PCV-2843